Cardiff Oncology Q2 2026: Strong Phase 2 Data, FDA Alignment on Phase 3, and Cash Runway into Q3 2027
CRDF sits 39% above its 52-week low of $0.757.
Summary
Cardiff Oncology's Q2 2026 update maps a clear route to a Phase 3 trial for onvansertib in first-line RAS-mutated mCRC, supported by robust Phase 2 data and FDA alignment. Cash runway extends into Q3 2027, though the existential license dispute with Nerviano Medical Sciences remains unresolved.
Key Events · Earnings and Guidance · CRDF
-
Phase 2 Data Shows 72.2% ORR
In first-line RAS-mutated mCRC, the 30 mg onvansertib + FOLFIRI/bev arm delivered a confirmed ORR of 72.2% versus 42.1% for standard-of-care alone, with a PFS hazard ratio of 0.55.
-
FDA Aligns on Phase 3 Trial Design
After a successful End-of-Phase 2 meeting, the FDA agreed on key elements of a registrational Phase 3 trial, which Cardiff plans to initiate in Q1 2027, subject to additional financing.
-
Cash Runway Extended into Q3 2027
With $34.5M in cash as of June 30, 2026, and a $10M July registered direct offering, the company believes its resources are sufficient to fund operations into Q3 2027, past the planned Phase 3 start.
-
License Dispute Remains Critical Risk
Nerviano Medical Sciences has purported to terminate the onvansertib license agreement; Cardiff is contesting this in court. An adverse outcome could derail the entire program.
Analysis · CRDF · Life Sciences
Cardiff Oncology's Q2 2026 results came with a business update that meaningfully advances its lead program. At ASCO, the company presented positive Phase 2 data showing a 72.2% ORR for onvansertib plus standard-of-care versus 42.1% for standard-of-care alone in first-line RAS-mutated mCRC. An End-of-Phase 2 meeting with the FDA then yielded alignment on a registrational Phase 3 trial design, with initiation planned for Q1 2027 — a clear path to a potential approval. Financially, the quarter ended with $34.5 million in cash, and a $10 million July offering extends the runway into Q3 2027, past the Phase 3 start. However, the ongoing license dispute with Nerviano Medical Sciences remains a critical risk — if the termination is upheld, the entire program is at risk. The combination of strong clinical data, regulatory clarity, and extended funding makes this a pivotal update for a company that had a going concern warning just three months ago.
At the time of this filing, CRDF was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.9M. The 52-week trading range was $0.76 to $3.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.